What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Statistics
Benjamin Djulbegovic mainly investigates Internal medicine, Randomized controlled trial, MEDLINE, Surgery and Oncology.
His study in Meta-analysis, Clinical trial, Multiple myeloma, Cancer and Neutropenia are all subfields of Internal medicine.
His Randomized controlled trial research includes themes of Odds ratio, Intensive care medicine and Hazard ratio, Confidence interval.
As a part of the same scientific study, Benjamin Djulbegovic usually deals with the MEDLINE, concentrating on Guideline and frequently concerns with Family medicine.
His work deals with themes such as Research design and Observational study, which intersect with Oncology.
In his study, Alternative medicine is strongly linked to Systematic review, which falls under the umbrella field of Evidence-based medicine.
His most cited work include:
- Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials (354 citations)
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study (257 citations)
- Progress in evidence-based medicine: a quarter century on. (237 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Randomized controlled trial, Oncology, Intensive care medicine and Clinical trial are his primary areas of study.
Adverse effect is closely connected to Surgery in his research, which is encompassed under the umbrella topic of Internal medicine.
His work is dedicated to discovering how Randomized controlled trial, Alternative medicine are connected with Family medicine and other disciplines.
His studies deal with areas such as Psychological intervention, Cancer and Disease as well as Intensive care medicine.
His studies in Clinical trial integrate themes in fields like Research design and Clinical research.
Benjamin Djulbegovic has researched Evidence-based medicine in several fields, including Guideline and Systematic review.
He most often published in these fields:
- Internal medicine (39.75%)
- Randomized controlled trial (29.50%)
- Oncology (18.50%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (39.75%)
- MEDLINE (13.50%)
- Evidence-based medicine (11.75%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, MEDLINE, Evidence-based medicine, Intensive care medicine and Oncology.
His studies in Meta-analysis, Randomized controlled trial, Myeloid leukemia, Hazard ratio and Zoledronic acid are all subfields of Internal medicine research.
The study incorporates disciplines such as Odds ratio, Adverse effect and Confidence interval in addition to Randomized controlled trial.
His MEDLINE research is multidisciplinary, incorporating perspectives in Guideline and Sample size determination.
The various areas that Benjamin Djulbegovic examines in his Evidence-based medicine study include Systematic review, Decision theory, Family medicine and Health policy.
His Intensive care medicine research incorporates elements of Cancer, Hematology, Venous thromboembolism, Evidence-based practice and Disease.
Between 2016 and 2021, his most popular works were:
- Progress in evidence-based medicine: a quarter century on. (237 citations)
- Progress in evidence-based medicine: a quarter century on. (237 citations)
- Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium (83 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Statistics
His primary areas of investigation include Internal medicine, MEDLINE, Randomized controlled trial, Meta-analysis and Evidence-based medicine.
He integrates many fields, such as Internal medicine and Hypomethylating agent, in his works.
His MEDLINE research includes elements of Cancer, Sample size determination and Intensive care medicine.
Benjamin Djulbegovic combines subjects such as Survival analysis and Confidence interval with his study of Randomized controlled trial.
His Meta-analysis research is multidisciplinary, relying on both Phase iii trials, Progression-free survival, Oncology and Daratumumab.
Benjamin Djulbegovic interconnects Decision theory, Historical Article and Critical appraisal in the investigation of issues within Evidence-based medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
